Literature DB >> 12975027

Insulin therapy for type 2 diabetes.

Afshin Sasali1, Jack L Leahy.   

Abstract

Type 2 diabetes is a disease of insulin deficiency along with insulin resistance, and the natural history is a progressive worsening of insulin secretion over time. The obvious conclusion supported by clinical experience is most patients will eventually need insulin therapy. However, there is often a reluctance on the part of many care providers to prescribe insulin because of fears of weight gain, hypoglycemia, or cardiovascular consequences, or because the patient is unwilling. Another problem is many practitioners are uncertain how to use insulin in type 2 diabetes. This review discusses the benefits of insulin therapy in patients with type 2 diabetes when it is required for optimal glycemia control. It also debunks the fears over unwanted consequences such as severe hypoglycemia and worsening of atherosclerotic cardiovascular disease. Finally, it provides a "hands on" approach on how to start basal insulin therapy and multishot insulin therapy in type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12975027     DOI: 10.1007/s11892-003-0081-2

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  51 in total

1.  Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients.

Authors:  John A Kiayias; Eugenia D Vlachou; Eleni Theodosopoulou; Elli Lakka-Papadodima
Journal:  Diabetes Care       Date:  2002-07       Impact factor: 19.112

2.  Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).

Authors:  Alex Wright; A C Felix Burden; Richard B Paisey; Carole A Cull; Rury R Holman
Journal:  Diabetes Care       Date:  2002-02       Impact factor: 19.112

3.  Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.

Authors:  J Rosenstock; S L Schwartz; C M Clark; G D Park; D W Donley; M B Edwards
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

4.  Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study.

Authors:  K Malmberg; A Norhammar; H Wedel; L Rydén
Journal:  Circulation       Date:  1999-05-25       Impact factor: 29.690

5.  Combination of insulin and metformin in the treatment of type 2 diabetes.

Authors:  Michiel G Wulffelé; Adriaan Kooy; Philippe Lehert; Daniel Bets; Jeles C Ogterop; Bob Borger van der Burg; Ab J M Donker; Coen D A Stehouwer
Journal:  Diabetes Care       Date:  2002-12       Impact factor: 19.112

6.  Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment.

Authors:  H Ilkova; B Glaser; A Tunçkale; N Bagriaçik; E Cerasi
Journal:  Diabetes Care       Date:  1997-09       Impact factor: 19.112

7.  Inhaled human insulin treatment in patients with type 2 diabetes mellitus.

Authors:  W T Cefalu; J S Skyler; I A Kourides; W H Landschulz; C C Balagtas; S Cheng; R A Gelfand
Journal:  Ann Intern Med       Date:  2001-02-06       Impact factor: 25.391

8.  U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.

Authors: 
Journal:  Diabetes       Date:  1995-11       Impact factor: 9.461

Review 9.  Novel insulins: expanding options in diabetes management.

Authors:  John E Gerich
Journal:  Am J Med       Date:  2002-09       Impact factor: 4.965

10.  The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus.

Authors:  W T Garvey; J M Olefsky; J Griffin; R F Hamman; O G Kolterman
Journal:  Diabetes       Date:  1985-03       Impact factor: 9.461

View more
  2 in total

Review 1.  Intensification of insulin therapy in patients with type 2 diabetes mellitus: an algorithm for basal-bolus therapy.

Authors:  Martin J Abrahamson; Anne Peters
Journal:  Ann Med       Date:  2012-07-23       Impact factor: 4.709

2.  Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis.

Authors:  Ajay Chaudhuri; Julio Rosenstock; Andres DiGenio; Luigi Meneghini; Priscilla Hollander; Janet B McGill; Paresh Dandona; John Ilgenfritz; Matthew Riddle
Journal:  Diabetes Metab Res Rev       Date:  2012-03       Impact factor: 4.876

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.